• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hepatobiliary and Pancreatic: Nivolumab-related cholangiopathy.

作者信息

Hamoir C, de Vos M, Clinckart F, Nicaise G, Komuta M, Lanthier N

机构信息

Department of Hepatogastroenterology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.

Department of Hepatogastroenterology, Jolimont Hospital, La Louvière, Belgium.

出版信息

J Gastroenterol Hepatol. 2018 Oct;33(10):1695. doi: 10.1111/jgh.14136. Epub 2018 Apr 29.

DOI:10.1111/jgh.14136
PMID:29707809
Abstract
摘要

相似文献

1
Hepatobiliary and Pancreatic: Nivolumab-related cholangiopathy.肝胆胰：与纳武利尤单抗相关的胆管病。
J Gastroenterol Hepatol. 2018 Oct;33(10):1695. doi: 10.1111/jgh.14136. Epub 2018 Apr 29.
2
Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer.非小细胞肺癌患者中纳武利尤单抗相关（诱导性）溃疡性胆管炎的经口胆管镜检查
Endoscopy. 2018 Sep;50(9):E259-E261. doi: 10.1055/a-0640-2392. Epub 2018 Jul 3.
3
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event.尼伏鲁单抗相关性胆管炎 1 例并文献复习：如何寻找正确的工具以正确诊断这种罕见的免疫相关不良事件。
Invest New Drugs. 2018 Feb;36(1):144-146. doi: 10.1007/s10637-017-0484-6. Epub 2017 Jun 20.
4
Recurrent Pyogenic Cholangitis: Got Stones?复发性化脓性胆管炎：有结石吗？
Dig Dis Sci. 2016 Nov;61(11):3147-3150. doi: 10.1007/s10620-015-3973-5. Epub 2015 Nov 24.
5
Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.三例与用于治疗非小细胞肺癌的抗程序性细胞死亡和程序性细胞死亡配体药物相关的免疫性胆管炎。
Eur J Cancer. 2019 Jul;115:107-110. doi: 10.1016/j.ejca.2019.04.022. Epub 2019 May 24.
6
Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy.重症肌无力与免疫检查点抑制剂治疗相关的恶化。
J Neuromuscul Dis. 2017;4(2):169-173. doi: 10.3233/JND-170219.
7
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.尼伏单抗相关胆管炎在非小细胞肺癌患者的影像学和临床病理特征。
Invest New Drugs. 2017 Aug;35(4):529-536. doi: 10.1007/s10637-017-0453-0. Epub 2017 Mar 20.
8
Immune-mediated cholangitis: is it always nivolumab's fault?免疫介导的胆管炎：这总是纳武单抗的错吗？
Cancer Immunol Immunother. 2018 Aug;67(8):1325-1327. doi: 10.1007/s00262-018-2159-3. Epub 2018 Apr 5.
9
Response to "Immune-mediated cholangitis: is it always nivolumab's fault?".对《免疫介导的胆管炎：总是纳武单抗的错吗？》的回应
Cancer Immunol Immunother. 2018 Aug;67(8):1329-1330. doi: 10.1007/s00262-018-2163-7. Epub 2018 Apr 26.
10
Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab.纳武利尤单抗诱导的大胆管胆管病用熊去氧胆酸和托珠单抗治疗。
Immunotherapy. 2019 Dec;11(18):1527-1531. doi: 10.2217/imt-2019-0121. Epub 2019 Dec 2.

引用本文的文献

1
Immune-Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges.免疫检查点抑制剂介导的肝损伤：一个充满新挑战的前沿领域。
Liver Int. 2025 Feb;45(2):e16198. doi: 10.1111/liv.16198.
2
Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives.癌症免疫治疗中的肝毒性：诊断、管理及未来展望。
Cancers (Basel). 2024 Dec 29;17(1):76. doi: 10.3390/cancers17010076.
3
Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review.老年非小细胞肺癌患者的免疫治疗：一项叙述性综述
J Clin Med. 2023 Feb 24;12(5):1833. doi: 10.3390/jcm12051833.
4
Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach.检查点抑制剂诱导的肝毒性：肝活检的作用及管理方法
World J Hepatol. 2022 Jul 27;14(7):1269-1276. doi: 10.4254/wjh.v14.i7.1269.
5
Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: A case report.纳武单抗治疗后发生的免疫球蛋白G4相关性自身免疫性胆管炎和胰腺炎：一例报告
World J Clin Cases. 2022 Jul 16;10(20):7124-7129. doi: 10.12998/wjcc.v10.i20.7124.
6
Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies.生物制剂所致肝毒性：临床特征与当前争议
J Clin Transl Hepatol. 2022 Jun 28;10(3):486-495. doi: 10.14218/JCTH.2021.00243. Epub 2022 Jan 25.
7
Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings.免疫检查点抑制剂相关胰腺炎和胆管炎的临床特征，包括影像学和内镜检查结果
Healthcare (Basel). 2022 Apr 20;10(5):763. doi: 10.3390/healthcare10050763.
8
Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.免疫检查点抑制剂所致免疫相关性胆管炎：临床特征与管理的系统评价。
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e858-e867. doi: 10.1097/MEG.0000000000002280.
9
Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci .延续有关免疫相关肝毒性的讨论：作者对 Gauci 博士的回复。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2021-002391.
10
Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient.帕博利珠单抗诱发的非小细胞肺癌患者继发性硬化性胆管炎
Respirol Case Rep. 2020 Apr 10;8(5):e00560. doi: 10.1002/rcr2.560. eCollection 2020 Jul.